NUCYNTA
Clinical safety rating
cautionComprehensive clinical and safety monograph for NUCYNTA (NUCYNTA).
Tapentadol is a centrally acting analgesic with dual mechanisms of action: mu-opioid receptor agonism and norepinephrine reuptake inhibition.
| Metabolism | Tapentadol is primarily metabolized via glucuronidation (UGT1A9 and UGT2B7) and to a lesser extent by CYP2C9 and CYP2D6; no active metabolites. |
| Excretion | Primarily renal excretion (approximately 95% of the dose is excreted in urine as tapentadol and its conjugates; <1% excreted unchanged in feces). |
| Half-life | Terminal elimination half-life is approximately 4 hours (range 3-5 hours); no significant accumulation with repeated dosing at recommended intervals. |
| Protein binding | Approximately 20% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | Volume of distribution is approximately 540 L (or 7.7 L/kg for a 70 kg individual), indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability is approximately 32% (due to extensive first-pass metabolism; absolute bioavailability is 32% for tapentadol HCl). |
| Onset of Action | Oral: Analgesic effect begins within 30-60 minutes; peak effect occurs at 1-2 hours. |
| Duration of Action | Duration of analgesia is approximately 4-6 hours with immediate-release formulation; dose interval is every 4-6 hours as needed. |
| Molecular Weight | 221.34 |
50-100 mg orally every 4-6 hours as needed for pain; maximum 600 mg/day.
| Dosage form | SOLUTION |
| Renal impairment | For GFR 30-59 mL/min: 50 mg every 6 hours; maximum 300 mg/day. For GFR 15-29 mL/min: 50 mg every 8 hours; maximum 200 mg/day. For GFR <15 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment needed. Child-Pugh B: 50 mg every 8 hours; maximum 300 mg/day. Child-Pugh C: not recommended. |
| Pediatric use | Not approved for use in patients under 18 years of age. |
| Geriatric use | For patients over 65 years, consider starting at 50 mg every 6 hours; maximum 300 mg/day due to potential renal impairment. |
| 1st trimester | Limited human data; animal studies show no evidence of teratogenicity; use only if benefit outweighs risk. |
| 2nd trimester | Limited human data; no specific risks identified; use with caution. |
| 3rd trimester | Prolonged use may cause neonatal opioid withdrawal and respiratory depression; avoid near term. |
Clinical note
Comprehensive clinical and safety monograph for NUCYNTA (NUCYNTA).
| Placental transfer | Tapentadol crosses the placenta; fetal plasma concentrations are approximately 20-30% of maternal levels. |
| Breastfeeding | Tapentadol is excreted into breast milk in low amounts (<0.1% of maternal dose); theoretical risk of infant opioid effects; use with caution, especially in infants <1 month old or with other CNS depressants. |
| Lactation Rating | L2 (Possibly Compatible) |
| Teratogenic Risk | First trimester: Limited human data; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Use may lead to neonatal opioid withdrawal syndrome (NOWS) with prolonged exposure. Avoid in third trimester near term due to risk of respiratory depression in the neonate. |
| Fetal Monitoring | Monitor maternal respiratory status, sedation, and bowel function; fetal heart rate monitoring during labor; neonatal assessment for signs of opioid withdrawal or respiratory depression at birth. |
| Fertility Effects | No clinical data on fertility effects in humans; animal studies indicate no significant impact on reproductive parameters at therapeutic doses. |
■ FDA Black Box Warning
Risk of addiction, abuse, and misuse, which can lead to overdose and death. Concomitant use with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death.
| Serious Effects |
Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI therapySignificant respiratory depressionAcute or severe bronchial asthma in unmonitored settings or without resuscitative equipmentKnown or suspected gastrointestinal obstruction, including paralytic ileusHypersensitivity to tapentadol or any component of the product
| Precautions | Serotonin syndrome with concurrent use of serotonergic drugs; risk of seizures in patients with seizure disorders; respiratory depression; risk of adrenal insufficiency; severe hypotension; risk of misuse and abuse. |
| Food/Dietary | Grapefruit and grapefruit juice may increase tapentadol levels by inhibiting CYP2C9 metabolism; avoid concurrent consumption. Alcohol potentiates CNS depression and should be avoided. High-fat meals may increase absorption of extended-release tablets; take consistently with regard to meals. No other specific food restrictions apply, but maintain a balanced diet to support overall health. |
| Clinical Pearls | NUCYNTA (tapentadol) is a centrally acting analgesic with mu-opioid receptor agonism and norepinephrine reuptake inhibition. It has a lower incidence of gastrointestinal side effects compared to traditional opioids but can still cause constipation. Avoid use in patients with severe hepatic impairment (Child-Pugh C). Tapentadol has no clinically relevant QTc prolongation. It is contraindicated in patients with significant respiratory depression, acute or severe bronchial asthma, or paralytic ileus. Monitor for serotonin syndrome when combined with serotonergic drugs. Immediate-release formulation has a rapid onset of 30-40 minutes and duration of 4-6 hours. Do not crush or chew extended-release tablets. Withdrawal may occur with abrupt discontinuation after prolonged use. |
| Patient Advice | Take NUCYNTA exactly as prescribed; do not increase dose or frequency without consulting your doctor. · Avoid alcohol and sedatives (e.g., benzodiazepines) as they increase risk of severe drowsiness, respiratory depression, and coma. · Do not drive or operate heavy machinery until you know how NUCYNTA affects you, as it may cause dizziness, drowsiness, or blurred vision. · Swallow immediate-release tablets whole, with or without food. Swallow extended-release tablets whole; do not crush, chew, or dissolve them. · Do not stop taking NUCYNTA abruptly after prolonged use; your doctor will taper your dose to avoid withdrawal symptoms such as anxiety, sweating, and diarrhea. · Store NUCYNTA in a secure place away from children and others; accidental ingestion can be fatal. · Contact your doctor immediately if you experience difficulty breathing, severe constipation, signs of serotonin syndrome (e.g., agitation, hallucinations, fast heart rate), or symptoms of adrenal insufficiency (nausea, vomiting, loss of appetite). · Inform your doctor about all other medications, including prescription, OTC, and herbal products, especially those for depression, migraine, or blood pressure. · Take missed doses as soon as remembered unless it is near the time of the next dose; do not double the dose. · NUCYNTA may cause constipation; increase fluid intake, fiber, and physical activity; ask your doctor about stool softeners if needed. |
Loading safety data…